Paclitaxel coated balloon - Lutonix/C.R. Bard

Drug Profile

Paclitaxel coated balloon - Lutonix/C.R. Bard

Alternative Names: Lutonix; Lutonix 35 drug coated balloon PTA catheter; Lutonix DCB; Lutonix paclitaxel DCB; Lutonix paclitaxel-coated balloon - Lutonix/CR Bard; Lutonix paclitaxel-coated PTA dilatation catheter; Lutonix® Drug Coated PTA Dilatation Catheter; MD02-LDCB; Paclitaxel-coated percutaneous transluminal angioplasty balloon - Lutonix/CR Bard

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lutonix
  • Developer CR Bard; Lutonix
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders

Most Recent Events

  • 25 Jun 2015 Updated efficacy results from the Levant 2 phase II trial in Peripheral arterial disorders released by C.R. Bard
  • 23 Oct 2014 Launched for Peripheral arterial disorders in USA (Intra-arterial)
  • 10 Oct 2014 Registered for Peripheral arterial disorders in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top